ArticleOncology and therapy2024

Cost-effectiveness of Pembrolizumab in Combination with Chemotherapy as Neoadjuvant Treatment and Continued as a Single Agent Adjuvant Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer in Hong Kong.

Ava Kwong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.